REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. on March 3, 2016, covering events occurring on March 1, 2016. The filing primarily references the company's financial results for the full year and quarter ended December 31, 2015, which were detailed in a press release furnished as Exhibit 99.1.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this Form 8-K.
Material Changes and Corporate Events
- Board Departure: Edgar G. Engleman, M.D., notified the Board on March 1, 2016, that he will not stand for re-election at the 2016 Annual Meeting to focus on other commitments.
- Board Composition: The number of directors will be reduced from eight to seven effective upon the expiration of Dr. Engleman's term at the Annual Meeting.
- Annual Meeting: The company announced its first Annual Meeting of Stockholders since becoming a public company in September 2015. The meeting is scheduled for June 1, 2016, at the company's Rockville, Maryland offices.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated March 3, 2016) for actual financial performance data for the year and quarter ended December 31, 2015.
- Confirm the reduction of the Board of Directors from eight to seven members following the June 1, 2016, Annual Meeting.
- Note that this is the company's first Annual Meeting since its initial public offering in September 2015.